Clinical trial NCT00486382: Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India
Official title: A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Visceral Leishmaniasis
Post-kala-azar Dermal Leishmaniasis
Keywords: visceral leishmaniasis
vaccine
Lead sponsor: Access to Advanced Health Institute (AAHI)
Sponsor class: OTHER
Collaborators: name: Bill and Melinda Gates Foundation
First posted: 2007-06-14
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 54
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if a vaccine (called Leish-111f + MPL-SE) is safe and whether it can or cannot produce a protective response against visceral leishmaniasis when injected to healthy subjects.

Detailed description: The purpose of this study is to determine the safety, tolerability, and immunogenicity of an investigational vaccine being developed for immunotherapy of visceral leishmaniasis (VL) and post kala-azar dermal leishmaniasis (PKDL). The vaccine, identified as Leish-111f + MPL-SE, consists of a recombinant three-antigen Leishmania polyprotein (Leish-111f) together with adjuvant MPL-SE.

The primary objective is to evaluate the safety and tolerability of the Leish-111f + MPL-SE vaccine given as three subcutaneous injections every 28 days at each of three dose levels of the Leish-111f protein (5 μg, 10 μg, or 20 μg) together with MPL-SE adjuvant (25 μg) in healthy adults.

The secondary objective is to assess the immunogenicity of the vaccine by evaluating T-cell and antibody response to the Leish-111f protein of the vaccine.

Eligibility criteria: Inclusion Criteria:

* Males and females ≥ 18 years and \< 55 years of age.
* Must be in good general health as confirmed by a medical history and physical exam.
* DAT titer must be \<1:400 and rK39 serology negative (for inclusion in the DAT-negative group) or DAT titer ≥1:1600 (for inclusion in the DAT-positive group).
* The following laboratory blood tests must have values within the normal ranges at screening (Appendix 4): sodium, potassium, urea, ALT, AST, total bilirubin, creatinine, alkaline phosphatase, glucose, hemoglobin, total WBC count and platelet count.
* The following serology tests must be negative at screening: HIV 1/2, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody. All subjects will receive HIV related counseling prior to testing. Subjects with positive HIV test results will receive counseling at the University and will be referred to the national AIDS control program for treatment if appropriate.
* Subjects must give written informed consent, be willing and able to attend all required visits, have a permanent address, and be reachable by study site personnel.
* Female subjects of childbearing potential must have a negative urine pregnancy test at screening, a negative urine pregnancy test within 24 hours before study injection, must not be breast-feeding, and are required to use adequate contraception through Day 84 of the study. These precautions are necessary due to unknown effects that Leish-111f + MPL-SE might have in a fetus or newborn infant.

Exclusion Criteria:

* Previous exposure to Leishmania vaccines or experimental products containing MPL-SE.
* Participation in another experimental protocol or receipt of any investigational products within 30 days prior to the first administration of study injection.
* Known use of injected or oral corticosteroids within 6 weeks prior to the first administration of study injection.
* History of autoimmune disease or other causes of immunosuppressive states.
* History or evidence of any acute or chronic illness that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or the immunogenicity of the vaccine. (Potential subjects presenting with concomitant illness will be referred for clinical care.)
* History of use of any medication that, in the opinion of the Principal Investigator, may interfere with the evaluation of the safety or the immunogenicity of the vaccine.
* History of significant psychiatric illness.
* Known to be a current drug or alcohol abuser.
* Subjects with a history of previous anaphylaxis, severe allergic reaction to vaccines or unknown allergens, or allergic reaction to eggs.
* History of chronic headaches or migraine.
* Subjects who are unlikely to cooperate with the requirements of the study protocol.
* Subjects who are not permanent residents or who are planning to move to another town/city.

Primary outcomes:
measure: Injection site reactions
timeFrame: For 7 days following each injection.
Secondary outcomes:
Other outcomes:
Locations:
city: Varanasi
country: India
facility: Banaras Hindu University
state: Uttar Pradesh
Study officials:
affiliation: Banaras Hindu University
name: Shyam Sundar, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Access to Advanced Health Institute (AAHI)
name: Franco M Piazza, MD, MPh
role: STUDY_DIRECTOR
References: